Ajovy is one of the CGRP inhibitors used for migraine prevention. Approved for ages 6 and up, it's noted for its safety, tolerability, and benefits seen within the first month.

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab ...